Table 1

Proliferative liver lesions, relative liver weight, and serum enzymes

GenotypeTreatmentnMultiplicity*Liver weight (%)ALT§ALP§
Total≤23–4≥5
23 weeks of PB treatment
Car+/+DEN200.9 ± 0.20.80.104.49 ± 0.0535 ± 569 ± 2
Car+/+DEN+PB206.4 ± 1.85.60.60.25.89 ± 0.0748 ± 487 ± 3
Car−/−DEN151.2 ± 0.31.10.104.28 ± 0.0428 ± 281 ± 3
Car−/−DEN+PB170.4 ± 0.20.4004.76 ± 0.0830 ± 482 ± 4
32 weeks of PB treatment
Car+/+DEN203.7 ± 0.63.20.40.24.52 ± 0.1227 ± 273 ± 11
Car+/+DEN+PB2036.4 ± 4.227.75.53.28.57 ± 0.72133 ± 21161 ± 21
Car−/−DEN203.4 ± 0.83.10.20.14.33 ± 0.0827 ± 263 ± 2
Car−/−DEN+PB192.4 ± 0.72.30.104.32 ± 0.0828 ± 268 ± 2
  • * Grossly observed proliferative lesions/mouse ± SE.

  • Lesion size (in mm).

  • Relative to body weight ± SE.

  • § Units/liter ± SE.